Cargando…
Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients
BACKGROUND: With the interest in cancer immunotherapy, it may be possible to combine immunotherapy with bevacizumab and chemotherapy. We evaluated whether tumor-infiltrating immune cells are associated with the efficacy of chemotherapy with or without bevacizumab for the treatment of metastatic colo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873592/ https://www.ncbi.nlm.nih.gov/pubmed/33585196 http://dx.doi.org/10.3389/fonc.2020.581051 |
_version_ | 1783649416110931968 |
---|---|
author | Wang, Yixing Dong, Jun Quan, Qi Liu, Shousheng Chen, Xiuxing Cai, Xiuyu Qiu, Huijuan Zhang, Bei Guo, Guifang |
author_facet | Wang, Yixing Dong, Jun Quan, Qi Liu, Shousheng Chen, Xiuxing Cai, Xiuyu Qiu, Huijuan Zhang, Bei Guo, Guifang |
author_sort | Wang, Yixing |
collection | PubMed |
description | BACKGROUND: With the interest in cancer immunotherapy, it may be possible to combine immunotherapy with bevacizumab and chemotherapy. We evaluated whether tumor-infiltrating immune cells are associated with the efficacy of chemotherapy with or without bevacizumab for the treatment of metastatic colorectal cancer (mCRC). METHODS: This study enrolled mCRC patients on standard treatment with available detailed data and tumor tissue at Sun Yat-sen University Cancer Center between July 1, 2005, and October 1, 2017. CD3+ and CD8+ T cell densities examined by immunohistochemistry in both the tumor core (CT) and invasive margin (IM) were summed as the Immunoscore, and the CD8+/CD3+ T cell ratio was calculated. The predictive and prognostic efficacies of tumor-infiltrating immune cells for progression-free survival (PFS) and overall survival (OS) were analyzed with Kaplan-Meier and Cox analyses. RESULTS: The CD8+/CD3+ T cell ratio in the microenvironment was an independent prognostic factor for OS (28.12 mo vs. 16.56 mo, P = 0.017) among the 108 studied patients. In the chemotherapy only group, patients with a high Immunoscore had a high overall response rate (ORR, 40.0% vs. 60.0%, P = 0.022), those with a low CD8+/CD3+ T cell ratio in the microenvironment had a significantly longer PFS (8.64 mo vs. 6.01 mo, P = 0.017), and those with a high CD3+ T cell density in the CT had a longer OS (16.56 mo vs. 25.66 mo, P = 0.029). In the chemotherapy combined with bevacizumab group, patients with a higher CD8+ T cell density in the IM had a longer PFS (7.62 mo vs. 11.66 mo, P = 0.034) and OS (14.55 mo vs. 23.72 mo, P = 0.033). CONCLUSION: Immune cells in primary tumors play an important role in predicting mCRC treatment efficacy. CD8 predicts the effect of bevacizumab plus chemotherapy, while CD3 and CD8/CD3 predict chemotherapy efficacy. |
format | Online Article Text |
id | pubmed-7873592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78735922021-02-11 Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Wang, Yixing Dong, Jun Quan, Qi Liu, Shousheng Chen, Xiuxing Cai, Xiuyu Qiu, Huijuan Zhang, Bei Guo, Guifang Front Oncol Oncology BACKGROUND: With the interest in cancer immunotherapy, it may be possible to combine immunotherapy with bevacizumab and chemotherapy. We evaluated whether tumor-infiltrating immune cells are associated with the efficacy of chemotherapy with or without bevacizumab for the treatment of metastatic colorectal cancer (mCRC). METHODS: This study enrolled mCRC patients on standard treatment with available detailed data and tumor tissue at Sun Yat-sen University Cancer Center between July 1, 2005, and October 1, 2017. CD3+ and CD8+ T cell densities examined by immunohistochemistry in both the tumor core (CT) and invasive margin (IM) were summed as the Immunoscore, and the CD8+/CD3+ T cell ratio was calculated. The predictive and prognostic efficacies of tumor-infiltrating immune cells for progression-free survival (PFS) and overall survival (OS) were analyzed with Kaplan-Meier and Cox analyses. RESULTS: The CD8+/CD3+ T cell ratio in the microenvironment was an independent prognostic factor for OS (28.12 mo vs. 16.56 mo, P = 0.017) among the 108 studied patients. In the chemotherapy only group, patients with a high Immunoscore had a high overall response rate (ORR, 40.0% vs. 60.0%, P = 0.022), those with a low CD8+/CD3+ T cell ratio in the microenvironment had a significantly longer PFS (8.64 mo vs. 6.01 mo, P = 0.017), and those with a high CD3+ T cell density in the CT had a longer OS (16.56 mo vs. 25.66 mo, P = 0.029). In the chemotherapy combined with bevacizumab group, patients with a higher CD8+ T cell density in the IM had a longer PFS (7.62 mo vs. 11.66 mo, P = 0.034) and OS (14.55 mo vs. 23.72 mo, P = 0.033). CONCLUSION: Immune cells in primary tumors play an important role in predicting mCRC treatment efficacy. CD8 predicts the effect of bevacizumab plus chemotherapy, while CD3 and CD8/CD3 predict chemotherapy efficacy. Frontiers Media S.A. 2021-01-27 /pmc/articles/PMC7873592/ /pubmed/33585196 http://dx.doi.org/10.3389/fonc.2020.581051 Text en Copyright © 2021 Wang, Dong, Quan, Liu, Chen, Cai, Qiu, Zhang and Guo http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Yixing Dong, Jun Quan, Qi Liu, Shousheng Chen, Xiuxing Cai, Xiuyu Qiu, Huijuan Zhang, Bei Guo, Guifang Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients |
title | Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients |
title_full | Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients |
title_fullStr | Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients |
title_full_unstemmed | Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients |
title_short | Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients |
title_sort | immune cell infiltration of the primary tumor microenvironment predicted the treatment outcome of chemotherapy with or without bevacizumab in metastatic colorectal cancer patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873592/ https://www.ncbi.nlm.nih.gov/pubmed/33585196 http://dx.doi.org/10.3389/fonc.2020.581051 |
work_keys_str_mv | AT wangyixing immunecellinfiltrationoftheprimarytumormicroenvironmentpredictedthetreatmentoutcomeofchemotherapywithorwithoutbevacizumabinmetastaticcolorectalcancerpatients AT dongjun immunecellinfiltrationoftheprimarytumormicroenvironmentpredictedthetreatmentoutcomeofchemotherapywithorwithoutbevacizumabinmetastaticcolorectalcancerpatients AT quanqi immunecellinfiltrationoftheprimarytumormicroenvironmentpredictedthetreatmentoutcomeofchemotherapywithorwithoutbevacizumabinmetastaticcolorectalcancerpatients AT liushousheng immunecellinfiltrationoftheprimarytumormicroenvironmentpredictedthetreatmentoutcomeofchemotherapywithorwithoutbevacizumabinmetastaticcolorectalcancerpatients AT chenxiuxing immunecellinfiltrationoftheprimarytumormicroenvironmentpredictedthetreatmentoutcomeofchemotherapywithorwithoutbevacizumabinmetastaticcolorectalcancerpatients AT caixiuyu immunecellinfiltrationoftheprimarytumormicroenvironmentpredictedthetreatmentoutcomeofchemotherapywithorwithoutbevacizumabinmetastaticcolorectalcancerpatients AT qiuhuijuan immunecellinfiltrationoftheprimarytumormicroenvironmentpredictedthetreatmentoutcomeofchemotherapywithorwithoutbevacizumabinmetastaticcolorectalcancerpatients AT zhangbei immunecellinfiltrationoftheprimarytumormicroenvironmentpredictedthetreatmentoutcomeofchemotherapywithorwithoutbevacizumabinmetastaticcolorectalcancerpatients AT guoguifang immunecellinfiltrationoftheprimarytumormicroenvironmentpredictedthetreatmentoutcomeofchemotherapywithorwithoutbevacizumabinmetastaticcolorectalcancerpatients |